The Future of the Swiss Cannabis Market

After decriminalizing minor cannabis possession in 2012, Switzerland has made several advancements in developing progressive laws around cannabis and CBD. By legalizing sales of low-THC cannabis and CBD, it has positioned itself as an obvious and attractive option for domestic and international businesses looking to enter the European market.

While, medical cannabis remains surprisingly limited—with only two pharmacies licensed to dispense tinctures and oil concentrates to patients with serious or terminal illnesses—the government recently approved a pilot program to start cannabis trials for recreational use. With approximately 20,0000 cannabis users in Switzerland, the recreational market is estimated to be worth $500 million.

This panel aims to give a detailed overview on the future of the Swiss cannabis and CBD markets.

Peter Steger (Master of Law)

– Chairman of IGMedCann (Swiss Association of Pharmaceutical Companies producing Cannabis Medicines)

– Managing Director of Spagyrik Produktions AG (producer of cannabis extracts for Dr. Manfred Fankhauser, Bahnhofapotheke Langnau, Switzerland’s leading distribution and advice centre for cannabis drugs)

Dr. Sandra Schoenes

Sandra is a medical doctor and MBA from background with a track record in healthcare entrepreneurship and over 10 years of consulting experience for biopharmaceutical and diagnostic companies with a focus on market access and medical education. Sandra is passionate about improving patient and physician access to meaningful medicines and is convinced about the great potential of evidence-based whole plant cannabis treatments.

Dr Gian Trepp (PhD Biochemistry)

He founded GBT Pharma in June 2010 bringing with him over 20 years’ experience in building and managing international markets for healthcare brands. His previous roles have included a decade of senior positions for Vifor Pharma Ltd, a subsidiary of Swiss healthcare group Galenica.

He is currently the commercial director of Creso Pharma (ASX: CPH), a leading cannabis company.

Andrew David Petronanos

He is the Founder and CEO of FINELEAF., a consultancy firm in the European cannabis market helping to bridge the relationship between investors and the emerging cannabis market.

Yannik Schlup 

He is the founder and Chief Scientific Officer of Puregene AG. In this role, he leads corporate and business development, strategic planning, research direction, academic partnerships and government engagement of Puregene. Together with the Science and Technology teams, he coordinates the internationally oriented breeding goals of the company.

Roger Koch

Founder and CEO of Koch & Gsell AG, the owners of the HEIMAT brand, who have paved the way on establishing the leading smokable CBD cigarettes brand. Being sold in all major retail chains in Switzerland, Luxembourg and Belgium.

Tom Zuber

Tom Zuber is a Founder of Global Go, and a Founder and the Managing Partner of Zuber Lawler, which represents clients around the globe in languages covering 90% of the world’s population. At Zuber Lawler, Tom is the relationship partner for some 10 Fortune 500 clients of the firm, as well as funds and government entities.